SCHEMBL3869887

SCHEMBL3869887

O=C(NCc1cccc(O)c1)c1ccc(C(=O)N[C@@H](CNC(=O)c2ccc(Cl)cc2)C(=O)O)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.46
ROCK1 Q13464 1/20 0.46
ITGB1 P05556 2/20 0.45
ITGA4 P13612 2/20 0.45
ITGAL P20701 3/20 0.44
ITGB2 P05107 2/20 0.44
ICAM1 P05362 2/20 0.44
NPC1 O15118 2/20 0.44
ALDH1A1 P00352 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
ALOX12 P18054 1/20 0.44
HTT P42858 1/20 0.44
CXCR3 P49682 1/20 0.43
PPARG P37231 5/20 0.43
NR1H4 Q96RI1 1/20 0.42
CHRM3 P20309 1/20 0.42
TP53 P04637 1/20 0.42
MT-CO2 P00403 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12361222 0.95 ROCK2 (0.47) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3866516 0.95 ROCK2 (0.47) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3876648 0.95 ITGB1 (0.47) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3866004 0.94 ITGB1 (0.46) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3875583 0.93 MEN1 (0.45) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3876360 0.93 NPC1 (0.45) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3870373 0.93 PPARG (0.46) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL3866963 0.92 ITGB1 (0.45) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL13940467 0.91 ITGB1 (0.44) ROCK2ROCK1ITGB1ITGA4ITGAL
SCHEMBL7985368 0.91 ITGB1 (0.44) ROCK2ROCK1ITGB1ITGA4ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 US claimed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 US claimed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 US claimed
US-7491741-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-17 US disclosed
US-20070155671-A1 Diaminopropionic acid derivatives FOTOUHI NADER 2007-07-05 US disclosed
US-7217728-B2 Diaminopropionic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2007-05-15 US disclosed
US-20050080119-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2005-04-14 US disclosed
US-6803384-B2 FOR THERAPY OF REPERFUSION INJURY HOFFMANN-LA ROCHE INC. 2004-10-12 US disclosed
US-20040006236-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2004-01-08 US disclosed
US-20020052512-A1 Diaminopropionic acid derivatives FOTOUHI NADER (US) 2002-05-02 US disclosed
US-6331640-B1 TREATMENT OF REPERFUSION INJURIES HOFFMANN-LA ROCHE INC. 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006236-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A ROCK2 4245/4885ROCK1 3087/4885ITGB1 1498/4885
US-20020052512-A1 Diaminopropionic acid derivatives AIFM1, AIFM2, HIF1A ROCK2 4245/4885ROCK1 3087/4885ITGB1 1498/4885
US-20070155671-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 ROCK2 4148/4885ROCK1 3663/4885ITGB1 1894/4885
US-20050080119-A1 Diaminopropionic acid derivatives AIFM1, HIF1A, AIFM2 ROCK2 4148/4885ROCK1 3663/4885ITGB1 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.